NOTV
NASDAQInotiv Inc.
SectorHealth CareIndustryBiotechnology: Commercial Physical & Biological Resarch
Website
News25/Ratings9
News · 26 weeks28-50%
2025-10-262026-04-19
Mix1390d
- SEC Filings6(46%)
- Insider4(31%)
- Earnings2(15%)
- Other1(8%)
Latest news
25 items- SECInotiv Inc. filed SEC Form 8-K: Other Events8-K - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Other Events8-K - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Other Events8-K - Inotiv, Inc. (0000720154) (Filer)
- INSIDERChief Financial Officer Taylor Beth A. sold $846 worth of shares (2,888 units at $0.29), decreasing direct ownership by 2% to 145,480 units (SEC Form 4)4 - Inotiv, Inc. (0000720154) (Issuer)
- INSIDERChief Strategy Officer Sagartz John E sold $616 worth of shares (2,119 units at $0.29), decreasing direct ownership by 0.29% to 735,697 units (SEC Form 4)4 - Inotiv, Inc. (0000720154) (Issuer)
- INSIDERPresident and CEO Leasure Robert Jr. sold $4,964 worth of shares (16,810 units at $0.30), decreasing direct ownership by 1% to 1,256,215 units (SEC Form 4)4 - Inotiv, Inc. (0000720154) (Issuer)
- PRInotiv Provides Notice Regarding Cybersecurity IncidentWEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025. As previously described in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission (the "SEC") on August 18, 2025 and its subsequent SEC filings, Inotiv experienced a cybersecurity incident in early August 2025. While Inotiv currently has no indication that perso
- SECSEC Form 10-Q filed by Inotiv Inc.10-Q - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inotiv, Inc. (0000720154) (Filer)
- PRInotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update– First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million – First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million – Conference call scheduled for today at 8:30 am ET WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q1 FY 2026") ended December 31, 2025. Revenue by Segment (in millions of USD) Three Months Ende
- PRInotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Company will host a conference call that same day at 8:30 a.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-445-7795 (Domestic)1-785-424-1699 (International)INOTIV (Co
- INSIDERPresident and CEO Leasure Robert Jr. sold $57,034 worth of shares (113,297 units at $0.50), decreasing direct ownership by 8% to 1,273,025 units (SEC Form 4)4 - Inotiv, Inc. (0000720154) (Issuer)
- SECAmendment: SEC Form 10-K/A filed by Inotiv Inc.10-K/A - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Inotiv, Inc. (0000720154) (Filer)
- INSIDERSEC Form 4 filed by EVP, General Counsel & Sec'y Castetter Andrea4 - Inotiv, Inc. (0000720154) (Issuer)
- PRInotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug DiscoveryWEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced a strategic initiative to leverage LifeNet Health's proprietary TruVivo® within its Discovery and Translational Sciences business. LifeNet Health, a global leader in regenerative medicine, has developed the patented TruVivo® system, which uses primary human hepatocytes cultured with human-derived feeder cells to create physiologically relevant in vitro models. This technology provides a
- SECInotiv Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing8-K - Inotiv, Inc. (0000720154) (Filer)
- PRInotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics CapabilitiesWEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, and VUGENE, a multi-omics data analysis company providing advanced artificial intelligence (AI) and machine learning (ML) solutions for biomedical research, today announced a strategic collaboration designed to accelerate AI-assisted drug discovery and enhance data-driven insights across the drug development continuum. Through this partnership, Inotiv will integrate VUGENE's cloud-based bioinform
- SECSEC Form 10-K filed by Inotiv Inc.10-K - Inotiv, Inc. (0000720154) (Filer)
- SECInotiv Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inotiv, Inc. (0000720154) (Filer)
- PRInotiv Reports Fourth Quarter and Full Year Financial Results for Fiscal 2025 and Provides Business Update– Fourth quarter fiscal 2025 revenue up 5.9% to $138.1 million– Fiscal 2025 revenue increased 4.5% to $513.0 million– Fourth quarter fiscal 2025 operating loss decreased 48.5% to $6.8 million– Fiscal 2025 operating loss decreased 64.2% to $30.9 million– Conference call scheduled for today at 4:30 pm ET WEST LAFAYETTE, Ind., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced financial results for the three months ("Q4 FY 2025") ended September 30, 2025, and twelve mo
- INSIDERSEC Form 4 filed by Inotiv Inc.4 - Inotiv, Inc. (0000720154) (Issuer)
- PRInotiv Ranked Number 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™WEST LAFAYETTE, Ind., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Inotiv today announced it ranked 182nd on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. Inotiv's revenue grew 448% from fiscal year 2021 to fiscal year 2024, the measurement period for this year's rankings. Robert Leasure, Jr., President and Chief Executive Officer of Inotiv credits the company's ongoing success to its focus on clients, scientific partnership, and strategic growth. He said, "We are honored to be recognized as a Deloitte Technology Fast 500™ winner for the third con
- PRInotiv, Inc. to Report Fiscal 2025 Fourth Quarter and Full Year Financial Results and Host Conference Call on Wednesday, December 3, 2025WEST LAFAYETTE, Ind., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ:NOTV) (the "Company", or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2025 fourth quarter and full year ended September 30, 2025, on Wednesday, December 3, 2025, after the close of the stock market. The Company will host a conference call that same day at 4:30 p.m. Eastern Time to discuss the results. Interested parties may participate in the call by dialing: 1-800-225-9448 (Domestic)1-203-518-9708
- SECInotiv Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Inotiv, Inc. (0000720154) (Filer)